Summary & Overview
CPT 85530: Heparin–Protamine Tolerance Test
CPT code 85530 denotes a laboratory assay measuring heparin–protamine tolerance in patient blood, a diagnostic test relevant to anticoagulation management and perioperative care. Nationally, this code is used by hospital and clinical laboratories when assessing a patient’s response to heparin reversal with protamine, which can be important for surgical teams, cardiology, and anticoagulation services.
Key payers in typical analyses include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides a compact overview of clinical context and operational considerations related to CPT code 85530, and outlines what readers can expect: typical service setting and clinical indications, payer coverage patterns and coding considerations where available, and benchmarking and policy context when data permits. It summarizes common billing modifiers provided in the input and notes where input data is incomplete.
Readers will gain a clear description of the test and its service line, guidance on where the test is commonly performed, and a concise set of topics to explore further, including reimbursement benchmarking, payer policy comparisons, and coding compliance considerations. Data not supplied in the input is identified as such so readers know where to seek supplemental information.
Billing Code Overview
CPT code 85530 describes a laboratory test in which a lab analyst measures heparin–protamine tolerance in a patient's blood. This test evaluates the blood's response to heparin neutralization with protamine, typically used in clinical contexts where anticoagulation management and reversal are important.
-
Service type: Laboratory diagnostic test
-
Typical site of service: Clinical laboratory or hospital laboratory setting
Data not available in the input for payers, taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 62-year-old male scheduled for cardiac surgery with cardiopulmonary bypass is evaluated preoperatively for heparin–protamine tolerance. He has a history of coronary artery disease, prior myocardial infarction, and chronic atrial fibrillation managed with anticoagulation. The clinical team orders a laboratory heparin–protamine tolerance test to determine the patient’s coagulation response to standard heparin dosing and the capacity to neutralize heparin with protamine, informing intraoperative anticoagulation and reversal strategy.
The workflow: the surgeon or anesthesiologist requests testing in the preoperative evaluation or immediately before bypass. A blood sample is drawn by phlebotomy or in the operating room and sent to the clinical laboratory. A laboratory technologist performs the heparin–protamine tolerance assay per institutional protocol, records activated clotting time (ACT) or other coagulation endpoints before and after heparin administration and following protamine neutralization, documents results in the laboratory information system, and notifies the perioperative team. Results guide intraoperative heparin dosing, protamine reversal, and bleeding risk management.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — default state | Use when no special modifier applies to the service |